And what convinced you that trying to bridge that gap could be effective and helpful for founders?

Yeah, absolutely.

So, you know, when startups start in the medtech space, especially, you know, we're talking about deep tech here, either the IP has been licensed from university or it is a student-led startup with some very deep technological expertise.

And the first half, the first initial part of the development works well because they bank on support from the university.

They can get funding from non-dilutive funding sources like the SBIR grants.

But the moment they get to this threshold where they need to start the studies, right, to get through to the FDA approval, Those funding sources that they were depending on initially are not relevant anymore.

They need to raise dilutive money and they're too early and not fully de-risked.

So when you look at founders that are at that stage, how do you de-risk it in your mind? What signals do you look for as you're talking to those founders that indicate to you it could be a winner?